Display options
Cite
Alhakamy NA, Ahmed OAA, Ibrahim TS, et al. Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus. Pharmaceuticals (Basel). 2021;14(3)doi: 10.3390/ph14030178.
Alhakamy, N. A., Ahmed, O. A. A., Ibrahim, T. S., Aldawsari, H. M., Eljaaly, K., Fahmy, U. A., Alaofi, A. L., Caraci, F., & Caruso, G. (2021). Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus. Pharmaceuticals (Basel, Switzerland), 14(3), . https://doi.org/10.3390/ph14030178
Alhakamy, Nabil A, et al. "Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus." Pharmaceuticals (Basel, Switzerland) vol. 14,3 (2021). doi: https://doi.org/10.3390/ph14030178
Alhakamy NA, Ahmed OAA, Ibrahim TS, Aldawsari HM, Eljaaly K, Fahmy UA, Alaofi AL, Caraci F, Caruso G. Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus. Pharmaceuticals (Basel). 2021 Feb 24;14(3). doi: 10.3390/ph14030178. PMID: 33668390; PMCID: PMC7996174.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2021 Feb 24;14(3). doi: 10.3390/ph14030178.

Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus.

Pharmaceuticals (Basel, Switzerland)

Nabil A Alhakamy, Osama A A Ahmed, Tarek S Ibrahim, Hibah M Aldawsari, Khalid Eljaaly, Usama A Fahmy, Ahmed L Alaofi, Filippo Caraci, Giuseppe Caruso

Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  2. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  3. Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  4. King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  5. Department of Organic chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  6. Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  7. Pharmacy Practice and Science Department, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
  8. Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  9. Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
  10. Oasi Research Institute-IRCCS, 94018 Troina, Italy.

PMID: 33668390 PMCID: PMC7996174 DOI: 10.3390/ph14030178

Abstract

The outbreak of the COVID-19 pandemic in China has become an urgent health and economic challenge. There is a current race for developing strategies to treat and/or prevent COVID-19 worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes COVID-19. The aim of the present work was to evaluate the efficacy of the combined complex (nano-conjugates) of two FDA-approved drugs, sitagliptin (SIT) and glatiramer acetate (GA), against a human isolate of the SARS-CoV-2 virus. SIT-GA nano-conjugates were prepared according to a full three-factor bilevel (2

Keywords: 3CL protease; COVID-19; SARS-CoV-2; glatiramer acetate; nanoparticles; sitagliptin

References

  1. J Membr Biol. 2017 Apr;250(2):115-122 - PubMed
  2. FEBS Lett. 2014 Nov 3;588(21):3870-7 - PubMed
  3. Pharmacol Res. 2015 Oct;100:127-34 - PubMed
  4. Biochim Biophys Acta. 2015 Mar;1848(3):869-77 - PubMed
  5. Int J Nanomedicine. 2019 Jun 07;14:4247-4259 - PubMed
  6. Nanomaterials (Basel). 2018 Dec 10;8(12): - PubMed
  7. Nat Microbiol. 2020 Apr;5(4):536-544 - PubMed
  8. Int J Mol Sci. 2020 May 27;21(11): - PubMed
  9. Pharmaceutics. 2020 Jun 27;12(7): - PubMed
  10. J Med Chem. 2016 Jul 28;59(14):6595-628 - PubMed
  11. Molecules. 2020 May 08;25(9): - PubMed
  12. Discoveries (Craiova). 2020 Dec 16;8(4):e121 - PubMed
  13. Saudi Pharm J. 2018 Jan;26(1):64-70 - PubMed
  14. Antiviral Res. 2011 Nov;92(2):204-12 - PubMed
  15. Pol Arch Intern Med. 2020 Apr 30;130(4):304-309 - PubMed
  16. Int J Nanomedicine. 2012;7:5577-91 - PubMed
  17. Pharmaceuticals (Basel). 2020 Sep 18;13(9): - PubMed
  18. Front Pharmacol. 2020 Aug 07;11:1161 - PubMed
  19. Int J Antimicrob Agents. 2020 Aug;56(2):106055 - PubMed
  20. Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4): - PubMed
  21. Analyst. 2013 Dec 7;138(23):7070-4 - PubMed
  22. Front Immunol. 2015 Jul 27;6:386 - PubMed
  23. Microbiol Resour Announc. 2020 May 28;9(22): - PubMed
  24. Pharmaceuticals (Basel). 2020 Dec 04;13(12): - PubMed
  25. Diabetes Care. 2020 Dec;43(12):2999-3006 - PubMed
  26. Int J Nanomedicine. 2006;1(3):283-9 - PubMed
  27. Anal Methods. 2017 Jan 21;9(3):402-408 - PubMed
  28. Immun Ageing. 2020 Jun 30;17:21 - PubMed
  29. Science. 2020 Apr 24;368(6489):409-412 - PubMed
  30. Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1043-1051 - PubMed
  31. Pharmaceutics. 2020 Oct 11;12(10): - PubMed
  32. Crit Rev Clin Lab Sci. 2003 Jun;40(3):209-94 - PubMed
  33. Respir Res. 2020 Aug 27;21(1):224 - PubMed
  34. Int J Mol Sci. 2020 Jun 10;21(11): - PubMed
  35. Infect Drug Resist. 2020 Sep 22;13:3243-3254 - PubMed
  36. Biophys J. 2019 Jan 22;116(2):347-359 - PubMed
  37. Nat Rev Cardiol. 2020 Sep;17(9):543-558 - PubMed
  38. Pharmaceutics. 2020 Apr 11;12(4): - PubMed
  39. Acta Pharm. 2021 Jun 1;71(2):175-184 - PubMed
  40. Nature. 2020 Mar;579(7798):265-269 - PubMed

Publication Types

Grant support